Network Pharmacology and Experimental Validation of Qingwen Baidu Decoction Therapeutic Potential in COVID-19-related Lung Injury


Cite item

Full Text

Abstract

Background and Purpose:Coronavirus disease 2019 (COVID-19) is a lifethreatening disease worldwide due to its high infection and serious outcomes resulting from acute lung injury. Qingwen Baidu decoction (QBD), a well-known herbal prescription, has shown significant efficacy in patients with Coronavirus disease 2019. Hence, this study aims to uncover the molecular mechanism of QBD in treating COVID-19-related lung injury.

Methods:Traditional Chinese Medicine Systems Pharmacology database (TCMSP), DrugBanks database, and Chinese Knowledge Infrastructure Project (CNKI) were used to retrieve the active ingredients of QBD. Drug and disease targets were collected using UniProt and Online Mendelian Inheritance in Man databases (OMIM). The core targets of QBD for pneumonia were analyzed by the Protein-Protein Interaction Network (PPI), Gene Ontology (GO), and Kyoto Encyclopedia of Genes and Genomes (KEGG) to reveal the underlying molecular mechanisms. The analysis of key targets using molecular docking and animal experiments was also validated.

Results:A compound-direct-acting target network mainly containing 171 compounds and 110 corresponding direct targets was constructed. The key targets included STAT3, c-JUN, TNF-α, MAPK3, MAPK1, FOS, PPARG, MAPK8, IFNG, NFκB1, etc. Moreover, 117 signaling pathways mainly involved in cytokine storm, inflammatory response, immune stress, oxidative stress and glucose metabolism were found by KEGG. The molecular docking results showed that the quercetin, alanine, and kaempferol in QBD demonstrated the strongest affinity to STAT3, c- JUN, and TNF-α. Experimental results displayed that QBD could effectively reduce the pathological damage to lung tissue by LPS and significantly alleviate the expression levels of the three key targets, thus playing a potential therapeutic role in COVID-19.

Conclusion:QBD might be a promising therapeutic agent for COVID-19 via ameliorating STAT3-related signals.

About the authors

Pengyan Li

Department of Pharmacy, 302 Military Hospital of China

Email: info@benthamscience.net

Jianxia Wen

College of Pharmacy, Chengdu University of Traditional Chinese Medicine

Email: info@benthamscience.net

Shizhang Wei

Department of Pharmacy, 302 Military Hospital of China

Email: info@benthamscience.net

Ruisheng Li

Department of Pharmacy, 302 Military Hospital of China

Email: info@benthamscience.net

Xiao Ma

College of Pharmacy, Chengdu University of Traditional Chinese Medicine

Author for correspondence.
Email: info@benthamscience.net

Yanling Zhao

Department of Pharmacy, 302 Military Hospital of China

Author for correspondence.
Email: info@benthamscience.net

Ju Yang

College of Pharmacy, Chengdu University of Traditional Chinese Medicine

Email: info@benthamscience.net

Zhao Zhang

College of Pharmacy, Chengdu University of Traditional Chinese Medicine

Email: info@benthamscience.net

Honghong Liu

Department of Pharmacy, 302 Military Hospital of China

Email: info@benthamscience.net

Jiawei Wang

College of Pharmacy, Chengdu University of Traditional Chinese Medicine

Email: info@benthamscience.net

Shuying Xie

Department of Pharmacy, 302 Military Hospital of China

Email: info@benthamscience.net

References

  1. Ellul, M.A.; Benjamin, L.; Singh, B.; Lant, S.; Michael, B.D.; Easton, A.; Kneen, R.; Defres, S.; Sejvar, J.; Solomon, T. Neurological associations of COVID-19. Lancet Neurol., 2020, 19(9), 767-783. doi: 10.1016/S1474-4422(20)30221-0 PMID: 32622375
  2. Sayampanathan, A.A.; Heng, C.S.; Pin, P.H.; Pang, J.; Leong, T.Y.; Lee, V.J. Infectivity of asymptomatic versus symptomatic COVID-19. Lancet., 2021, 397(10269), 93-94. doi: 10.1016/S0140-6736(20)32651-9 PMID: 33347812
  3. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines; National Institutes of Health, 2019.
  4. COVID-19 treatment protocol (trial version 8). Available from: https://covid19.alliancebrh.com/covid19en/c100036/202008/12b9b42813a94755bbf442008fe86f63/files/b0ae9b6c1d9a47bf81d7dc1f5e7ddda5.pdf
  5. Shuren, L.; Wenjing, Z.; Jianchao, L.; Yang, M.; Xiao, H.; Qianhui, Z. A comparative analysis of the treatment guidelines for novel coronavirus pneumonia issued by the NIH in the United States in 2021 and the treatment protocols for novel coronavirus pneumonia issued in China. Chinese. Fam. Med., 2021, 24(14), 1735-1744.
  6. Shijing, Q.; Rainbow, W.; Ping, Z.; Zhongtian, Q. Progress of SARS-CoV-2 vaccine research. PLA Med. J., 2021, 46(07), 710-717.
  7. Folegatti, P.M.; Ewer, K.J.; Aley, P.K.; Angus, B.; Becker, S.; Belij-Rammerstorfer, S.; Bellamy, D.; Bibi, S.; Bittaye, M.; Clutterbuck, E.A.; Dold, C.; Faust, S.N.; Finn, A.; Flaxman, A.L.; Hallis, B.; Heath, P.; Jenkin, D.; Lazarus, R.; Makinson, R.; Minassian, A.M.; Pollock, K.M.; Ramasamy, M.; Robinson, H.; Snape, M.; Tarrant, R.; Voysey, M.; Green, C.; Douglas, A.D.; Hill, A.V.S.; Lambe, T.; Gilbert, S.C.; Pollard, A.J.; Aboagye, J.; Adams, K.; Ali, A.; Allen, E.; Allison, J.L.; Anslow, R.; Arbe-Barnes, E.H.; Babbage, G.; Baillie, K.; Baker, M.; Baker, N.; Baker, P.; Baleanu, I.; Ballaminut, J.; Barnes, E.; Barrett, J.; Bates, L.; Batten, A.; Beadon, K.; Beckley, R.; Berrie, E.; Berry, L.; Beveridge, A.; Bewley, K.R.; Bijker, E.M.; Bingham, T.; Blackwell, L.; Blundell, C.L.; Bolam, E.; Boland, E.; Borthwick, N.; Bower, T.; Boyd, A.; Brenner, T.; Bright, P.D.; Brown-O’Sullivan, C.; Brunt, E.; Burbage, J.; Burge, S.; Buttigieg, K.R.; Byard, N.; Cabera Puig, I.; Calvert, A.; Camara, S.; Cao, M.; Cappuccini, F.; Carr, M.; Carroll, M.W.; Carter, V.; Cathie, K.; Challis, R.J.; Charlton, S.; Chelysheva, I.; Cho, J-S.; Cicconi, P.; Cifuentes, L.; Clark, H.; Clark, E.; Cole, T.; Colin-Jones, R.; Conlon, C.P.; Cook, A.; Coombes, N.S.; Cooper, R.; Cosgrove, C.A.; Coy, K.; Crocker, W.E.M.; Cunningham, C.J.; Damratoski, B.E.; Dando, L.; Datoo, M.S.; Davies, H.; De Graaf, H.; Demissie, T.; Di Maso, C.; Dietrich, I.; Dong, T.; Donnellan, F.R.; Douglas, N.; Downing, C.; Drake, J.; Drake-Brockman, R.; Drury, R.E.; Dunachie, S.J.; Edwards, N.J.; Edwards, F.D.L.; Edwards, C.J.; Elias, S.C.; Elmore, M.J.; Emary, K.R.W.; English, M.R.; Fagerbrink, S.; Felle, S.; Feng, S.; Field, S.; Fixmer, C.; Fletcher, C.; Ford, K.J.; Fowler, J.; Fox, P.; Francis, E.; Frater, J.; Furze, J.; Fuskova, M.; Galiza, E.; Gbesemete, D.; Gilbride, C.; Godwin, K.; Gorini, G.; Goulston, L.; Grabau, C.; Gracie, L.; Gray, Z.; Guthrie, L.B.; Hackett, M.; Halwe, S.; Hamilton, E.; Hamlyn, J.; Hanumunthadu, B.; Harding, I.; Harris, S.A.; Harris, A.; Harrison, D.; Harrison, C.; Hart, T.C.; Haskell, L.; Hawkins, S.; Head, I.; Henry, J.A.; Hill, J.; Hodgson, S.H.C.; Hou, M.M.; Howe, E.; Howell, N.; Hutlin, C.; Ikram, S.; Isitt, C.; Iveson, P.; Jackson, S.; Jackson, F.; James, S.W.; Jenkins, M.; Jones, E.; Jones, K.; Jones, C.E.; Jones, B.; Kailath, R.; Karampatsas, K.; Keen, J.; Kelly, S.; Kelly, D.; Kerr, D.; Kerridge, S.; Khan, L.; Khan, U.; Killen, A.; Kinch, J.; King, T.B.; King, L.; King, J.; Kingham-Page, L.; Klenerman, P.; Knapper, F.; Knight, J.C.; Knott, D.; Koleva, S.; Kupke, A.; Larkworthy, C.W.; Larwood, J.P.J.; Laskey, A.; Lawrie, A.M.; Lee, A.; Ngan Lee, K.Y.; Lees, E.A.; Legge, H.; Lelliott, A.; Lemm, N-M.; Lias, A.M.; Linder, A.; Lipworth, S.; Liu, X.; Liu, S.; Lopez Ramon, R.; Lwin, M.; Mabesa, F.; Madhavan, M.; Mallett, G.; Mansatta, K.; Marcal, I.; Marinou, S.; Marlow, E.; Marshall, J.L.; Martin, J.; McEwan, J.; McInroy, L.; Meddaugh, G.; Mentzer, A.J.; Mirtorabi, N.; Moore, M.; Moran, E.; Morey, E.; Morgan, V.; Morris, S.J.; Morrison, H.; Morshead, G.; Morter, R.; Mujadidi, Y.F.; Muller, J.; Munera-Huertas, T.; Munro, C.; Munro, A.; Murphy, S.; Munster, V.J.; Mweu, P.; Noé, A.; Nugent, F.L.; Nuthall, E.; O’Brien, K.; O’Connor, D.; Oguti, B.; Oliver, J.L.; Oliveira, C.; O’Reilly, P.J.; Osborn, M.; Osborne, P.; Owen, C.; Owens, D.; Owino, N.; Pacurar, M.; Parker, K.; Parracho, H.; Patrick-Smith, M.; Payne, V.; Pearce, J.; Peng, Y.; Peralta Alvarez, M.P.; Perring, J.; Pfafferott, K.; Pipini, D.; Plested, E.; Pluess-Hall, H.; Pollock, K.; Poulton, I.; Presland, L.; Provstgaard-Morys, S.; Pulido, D.; Radia, K.; Ramos Lopez, F.; Rand, J.; Ratcliffe, H.; Rawlinson, T.; Rhead, S.; Riddell, A.; Ritchie, A.J.; Roberts, H.; Robson, J.; Roche, S.; Rohde, C.; Rollier, C.S.; Romani, R.; Rudiansyah, I.; Saich, S.; Sajjad, S.; Salvador, S.; Sanchez Riera, L.; Sanders, H.; Sanders, K.; Sapaun, S.; Sayce, C.; Schofield, E.; Screaton, G.; Selby, B.; Semple, C.; Sharpe, H.R.; Shaik, I.; Shea, A.; Shelton, H.; Silk, S.; Silva-Reyes, L.; Skelly, D.T.; Smee, H.; Smith, C.C.; Smith, D.J.; Song, R.; Spencer, A.J.; Stafford, E.; Steele, A.; Stefanova, E.; Stockdale, L.; Szigeti, A.; Tahiri-Alaoui, A.; Tait, M.; Talbot, H.; Tanner, R.; Taylor, I.J.; Taylor, V.; Te Water Naude, R.; Thakur, N.; Themistocleous, Y.; Themistocleous, A.; Thomas, M.; Thomas, T.M.; Thompson, A.; Thomson-Hill, S.; Tomlins, J.; Tonks, S.; Towner, J.; Tran, N.; Tree, J.A.; Truby, A.; Turkentine, K.; Turner, C.; Turner, N.; Turner, S.; Tuthill, T.; Ulaszewska, M.; Varughese, R.; Van Doremalen, N.; Veighey, K.; Verheul, M.K.; Vichos, I.; Vitale, E.; Walker, L.; Watson, M.E.E.; Welham, B.; Wheat, J.; White, C.; White, R.; Worth, A.T.; Wright, D.; Wright, S.; Yao, X.L.; Yau, Y. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: A preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet, 2020, 396(10249), 467-478. doi: 10.1016/S0140-6736(20)31604-4 PMID: 32702298
  8. Huang, C.; Wang, Y.; Li, X.; Ren, L.; Zhao, J.; Hu, Y.; Zhang, L.; Fan, G.; Xu, J.; Gu, X.; Cheng, Z.; Yu, T.; Xia, J.; Wei, Y.; Wu, W.; Xie, X.; Yin, W.; Li, H.; Liu, M.; Xiao, Y.; Gao, H.; Guo, L.; Xie, J.; Wang, G.; Jiang, R.; Gao, Z.; Jin, Q.; Wang, J.; Cao, B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet., 2020, 395(10223), 497-506. doi: 10.1016/S0140-6736(20)30183-5 PMID: 31986264
  9. Rodríguez-Morales, A.J.; MacGregor, K.; Kanagarajah, S.; Patel, D.; Schlagenhauf, P. Going global – Travel and the 2019 novel coronavirus. Travel Med. Infect. Dis., 2020, 33, 101578. doi: 10.1016/j.tmaid.2020.101578 PMID: 32044389
  10. Petrosillo, N.; Viceconte, G.; Ergonul, O.; Ippolito, G.; Petersen, E. COVID-19, SARS and MERS: Are they closely related? Clin. Microbiol. Infect., 2020, 26(6), 729-734. doi: 10.1016/j.cmi.2020.03.026 PMID: 32234451
  11. Mohamadian, M.; Chiti, H.; Shoghli, A.; Biglari, S.; Parsamanesh, N.; Esmaeilzadeh, A. COVID‐19: Virology, biology and novel laboratory diagnosis. J. Gene Med., 2021, 23(2), e3303. doi: 10.1002/jgm.3303 PMID: 33305456
  12. Chen, J.; Wenqing, W.; Chunyang, S.; Jianguo, F. Reflections on the prevention and treatment of novel coronavirus pneumonia (COVID-19) by Chinese medicine. Chin. Herb. Med., 2020, 51(05), 1106-1112.
  13. Wenling, C.; Jin, Z. Give full play to the unique advantages of Chinese medicine in China under the new situation should accelerate the construction of Chinese and Western medicine and health system. People's For. Acad. Front., 2021, 2021(12), 64-83.
  14. Ministry of Science and Technology: Chinese medicine involved in saving and treating more than 60,000 cases accounted for more than 85% of the cases;,
  15. Yuntong, L.; Zhe, W.; Jing, L.; Guilin, Z.; Youhua, X. Research progress on the role of Chinese medicine in COVID-19 inflammatory injury. Sci. Bull., 2021, 66(26), 3377-3384.
  16. Zhaoxiang, B. Improvement in the quality of clinical evidence of Chinese medicine against COVID-19. Sci. Bull., 2021, 66(26), 3372-3376.
  17. Wu, L-T.; Ying, C.; Yiwen, L.; Yueqin, Y.; Qixin, L. Multi-dimensional analysis of qi-yin and qi-yang syndrome in COVID-19. Chin. J. Integr. Med., 2020, 29(27), 2965-2969.
  18. Chen, M.L.; Shah, V.; Patnaik, R.; Adams, W.; Hussain, A.; Conner, D.; Mehta, M.; Malinowski, H.; Lazor, J.; Huang, S.M.; Hare, D.; Lesko, L.; Sporn, D.; Williams, R. Bioavailability and bioequivalence: An FDA regulatory overview. Pharm. Res., 2001, 18(12), 1645-1650. doi: 10.1023/A:1013319408893 PMID: 11785681
  19. Tao, W.; Xu, X.; Wang, X.; Li, B.; Wang, Y.; Li, Y.; Yang, L. Network pharmacology-based prediction of the active ingredients and potential targets of Chinese herbal Radix Curcumae formula for application to cardiovascular disease. J. Ethnopharmacol., 2013, 145(1), 1-10. doi: 10.1016/j.jep.2012.09.051 PMID: 23142198
  20. Fengrong, Z.; Na, Z.; Zhiyong, L.; Shihuan, T. Discussion on intervention mechanism of qingwen baidu decoction on cytokine storm based on network pharmacology. J. Tradit. Chin. Med., 2020, 45(07), 1499-1508.
  21. Shi, S.; Cai, Y.; Cai, X.; Zheng, X.; Cao, D.; Ye, F.; Xiang, Z. A network pharmacology approach to understanding the mechanisms of action of traditional medicine: Bushenhuoxue formula for treatment of chronic kidney disease. PLoS One, 2014, 9(3), e89123. doi: 10.1371/journal.pone.0089123 PMID: 24598793
  22. Jingjing, D.; Huajuan, J.; Xing, L.; Li, M.; Shengju, W.; Yao, H. Exploring the mechanism of synergistic effect of the classical formula Tao Hong Si Wu Tang based on network pharmacology and molecular docking. Chin. Herb. Med., 2021, 52(10), 3018-3029.
  23. Yang, J.; Xiao, L.; Fang, L.; Lujie, L.; Yuan, G.; Qi, Z. Mechanism of magnolia in the treatment of peptic ulcer based on network pharmacology and molecular docking. J. Tradit. Chin. Med., 2021, 46(17), 4522-4530. PMID: 34581058
  24. Xia, Q.D.; Xun, Y.; Lu, J.L.; Lu, Y.C.; Yang, Y.Y.; Zhou, P.; Hu, J.; Li, C.; Wang, S.G. Network pharmacology and molecular docking analyses on Lianhua Qingwen capsule indicate Akt1 is a potential target to treat and prevent COVID‐19. Cell Prolif., 2020, 53(12), e12949. doi: 10.1111/cpr.12949 PMID: 33140889
  25. Tao, Q.; Du, J.; Li, X.; Zeng, J.; Tan, B.; Xu, J.; Lin, W.; Chen, X. Network pharmacology and molecular docking analysis on molecular targets and mechanisms of Huashi Baidu formula in the treatment of COVID-19. Drug Dev. Ind. Pharm., 2020, 46(8), 1345-1353. doi: 10.1080/03639045.2020.1788070 PMID: 32643448
  26. Diagnosis and treatment protocol for COVID-19 patients (Trial Version 7). https://covid19.alliancebrh.com/covid19en/c100036/202008/12b9b42813a94755bbf442008fe86f63/files/b0ae9b6c1d9a47bf81d7dc1f5e7ddda5.pdf
  27. Wen, J.; Wang, R.; Liu, H.; Tong, Y.; Wei, S.; Zhou, X.; Li, H.; Jing, M.; Wang, M.; Zhao, Y. Potential therapeutic effect of Qingwen Baidu Decoction against Corona Virus Disease 2019: A mini review. Chin. Med., 2020, 15(1), 48. doi: 10.1186/s13020-020-00332-y PMID: 32454888
  28. Lee, B.H.; Chathuranga, K.; Uddin, M.B.; Weeratunga, P.; Kim, M.S.; Cho, W.K.; Kim, H.I.; Ma, J.Y.; Lee, J.S. Coptidis Rhizoma extract inhibits replication of respiratory syncytial virus in vitro and in vivo by inducing antiviral state. J. Microbiol., 2017, 55(6), 488-498. doi: 10.1007/s12275-017-7088-x PMID: 28551874
  29. Ratanakomol, T.; Roytrakul, S.; Wikan, N.; Smith, D.R. Berberine inhibits dengue virus through dual mechanisms. Molecules., 2021, 26(18), 5501. doi: 10.3390/molecules26185501 PMID: 34576974
  30. Robinson, C.L.; Chong, A.C.N.; Ashbrook, A.W.; Jeng, G.; Jin, J.; Chen, H.; Tang, E.I.; Martin, L.A.; Kim, R.S.; Kenyon, R.M.; Do, E.; Luna, J.M.; Saeed, M.; Zeltser, L.; Ralph, H.; Dudley, V.L.; Goldstein, M.; Rice, C.M.; Cheng, C.Y.; Seandel, M.; Chen, S. Male germ cells support long-term propagation of Zika virus. Nat. Commun., 2018, 9(1), 2090. doi: 10.1038/s41467-018-04444-w PMID: 29844387
  31. Zhang, F.; Yin, X.; Yan, Y.; Wu, Q. Pharmacokinetics and pharmacodynamics of huanglian-houpo decoction based on berberine hydrochloride and magnolol against H1N1 influenza virus. Eur. J. Drug Metab. Pharmacokinet., 2022, 47(1), 57-67. doi: 10.1007/s13318-021-00724-x PMID: 34635990
  32. Zhang, X.; Sun, X.; Wu, J.; Wu, Y.; Wang, Y.; Hu, X.; Wang, X. Berberine damages the cell surface of methicillin-resistant Staphylococcus aureus. Front. Microbiol., 2020, 11, 621. doi: 10.3389/fmicb.2020.00621 PMID: 32411101
  33. Rodriguez-Rodriguez, B.A.; Noval, M.G.; Kaczmarek, M.E.; Jang, K.K.; Thannickal, S.A.; Cifuentes Kottkamp, A.; Brown, R.S.; Kielian, M.; Cadwell, K.; Stapleford, K.A. Atovaquone and berberine chloride reduce SARS-CoV-2 replication in vitro. Viruses, 2021, 13(12), 2437. doi: 10.3390/v13122437 PMID: 34960706
  34. Bousquet, J.; Cristol, J.P.; Czarlewski, W.; Anto, J.M.; Martineau, A.; Haahtela, T.; Fonseca, S.C.; Iaccarino, G.; Blain, H.; Fiocchi, A.; Canonica, G.W.; Fonseca, J.A.; Vidal, A.; Choi, H.J.; Kim, H.J.; Le Moing, V.; Reynes, J.; Sheikh, A.; Akdis, C.A.; Zuberbier, T. Nrf2-interacting nutrients and COVID-19: Time for research to develop adaptation strategies. Clin. Transl. Allergy, 2020, 10(1), 58. doi: 10.1186/s13601-020-00362-7 PMID: 33292691
  35. Tarabasz, D.; Kukula-Koch, W. Palmatine: A review of pharmacological properties and pharmacokinetics. Phytother. Res., 2020, 34(1), 33-50. doi: 10.1002/ptr.6504 PMID: 31496018
  36. Cheng, D.; Liu, P.; Wang, Z. Palmatine attenuates the doxorubicin-induced inflammatory response, oxidative damage and cardiomyocyte apoptosis. Int. Immunopharmacol., 2022, 106, 108583. doi: 10.1016/j.intimp.2022.108583 PMID: 35151220
  37. Commission, N.P. Pharmacopoeia of the People’s Republic of China. Part I; China Medical Science and Technology Press: Beijing, 2020, p. 314.
  38. Wang, Z.L.; Wang, S.; Kuang, Y.; Hu, Z.M.; Qiao, X.; Ye, M. A comprehensive review on phytochemistry, pharmacology, and flavonoid biosynthesis of Scutellaria baicalensis. Pharm. Biol., 2018, 56(1), 465-484. doi: 10.1080/13880209.2018.1492620 PMID: 31070530
  39. Dinda, B.; Dinda, S.; DasSharma, S.; Banik, R.; Chakraborty, A.; Dinda, M. Therapeutic potentials of baicalin and its aglycone, baicalein against inflammatory disorders. Eur. J. Med. Chem., 2017, 131, 68-80. doi: 10.1016/j.ejmech.2017.03.004 PMID: 28288320
  40. Lucas, C.D.; Dorward, D.A.; Sharma, S.; Rennie, J.; Felton, J.M.; Alessandri, A.L.; Duffin, R.; Schwarze, J.; Haslett, C.; Rossi, A.G. Wogonin induces eosinophil apoptosis and attenuates allergic airway inflammation. Am. J. Respir. Crit. Care Med., 2015, 191(6), 626-636. doi: 10.1164/rccm.201408-1565OC PMID: 25629436
  41. Fanunza, E.; Iampietro, M.; Distinto, S.; Corona, A.; Quartu, M.; Maccioni, E.; Horvat, B.; Tramontano, E. Quercetin blocks ebola virus infection by counteracting the vp24 interferon-inhibitory function. Antimicrob. Agents Chemother., 2020, 64(7), e00530-20. doi: 10.1128/AAC.00530-20 PMID: 32366711
  42. Mehrbod, P.; Abdalla, M.A.; Fotouhi, F.; Heidarzadeh, M.; Aro, A.O.; Eloff, J.N.; McGaw, L.J.; Fasina, F.O. Immunomodulatory properties of quercetin-3-O-α-L-rhamnopyranoside from Rapanea melanophloeos against influenza a virus. BMC Complement. Altern. Med., 2018, 18(1), 184. doi: 10.1186/s12906-018-2246-1 PMID: 29903008
  43. Liu, Z.; Zhao, J.; Li, W.; Shen, L.; Huang, S.; Tang, J.; Duan, J.; Fang, F.; Huang, Y.; Chang, H.; Chen, Z.; Zhang, R. Computational screen and experimental validation of anti-influenza effects of quercetin and chlorogenic acid from traditional Chinese medicine. Sci. Rep., 2016, 6(1), 19095. doi: 10.1038/srep19095 PMID: 26754609
  44. Komaravelli, N.; Kelley, J.P.; Garofalo, M.P.; Wu, H.; Casola, A.; Kolli, D. Role of dietary antioxidants in human metapneumovirus infection. Virus Res., 2015, 200, 19-23. doi: 10.1016/j.virusres.2015.01.018 PMID: 25645280
  45. Galochkina, A.V.; Anikin, V.B.; Babkin, V.A.; Ostrouhova, L.A.; Zarubaev, V.V. Virus-inhibiting activity of dihydroquercetin, a flavonoid from Larix sibirica, against coxsackievirus B4 in a model of viral pancreatitis. Arch. Virol., 2016, 161(4), 929-938. doi: 10.1007/s00705-016-2749-3 PMID: 26780775
  46. Di Pierro, F.; Derosa, G.; Maffioli, P.; Bertuccioli, A.; Togni, S.; Riva, A.; Allegrini, P.; Khan, A.; Khan, S.; Khan, B.A.; Altaf, N.; Zahid, M.; Ujjan, I.D.; Nigar, R.; Khushk, M.I.; Phulpoto, M.; Lail, A.; Devrajani, B.R.; Ahmed, S. Possible therapeutic effects of adjuvant quercetin supplementation against early-stage COVID-19 infection: A prospective, randomized, controlled, and open-label study. Int. J. Gen. Med., 2021, 14, 2359-2366. doi: 10.2147/IJGM.S318720 PMID: 34135619
  47. Abian, O.; Ortega-Alarcon, D.; Jimenez-Alesanco, A.; Ceballos-Laita, L.; Vega, S.; Reyburn, H.T.; Rizzuti, B.; Velazquez-Campoy, A. Structural stability of SARS-CoV-2 3CLpro and identification of quercetin as an inhibitor by experimental screening. Int. J. Biol. Macromol., 2020, 164, 1693-1703. doi: 10.1016/j.ijbiomac.2020.07.235 PMID: 32745548
  48. Derosa, G.; Maffioli, P.; D’Angelo, A.; Di Pierro, F. A role for quercetin in coronavirus disease 2019 (COVID‐19). Phytother. Res., 2021, 35(3), 1230-1236. doi: 10.1002/ptr.6887 PMID: 33034398
  49. Colunga Biancatelli, R.M.L.; Berrill, M.; Catravas, J.D.; Marik, P.E. Quercetin and vitamin C: An experimental, synergistic therapy for the prevention and treatment of SARS-CoV-2 related disease (COVID-19). Front. Immunol., 2020, 11, 1451. doi: 10.3389/fimmu.2020.01451 PMID: 32636851
  50. Zhang, R.; Ai, X.; Duan, Y.; Xue, M.; He, W.; Wang, C.; Xu, T.; Xu, M.; Liu, B.; Li, C.; Wang, Z.; Zhang, R.; Wang, G.; Tian, S.; Liu, H. Kaempferol ameliorates H9N2 swine influenza virus-induced acute lung injury by inactivation of TLR4/MyD88-mediated NF-κB and MAPK signaling pathways. Biomed. Pharmacother., 2017, 89, 660-672. doi: 10.1016/j.biopha.2017.02.081 PMID: 28262619
  51. Sekine-Osajima, Y.; Sakamoto, N.; Nakagawa, M.; Itsui, Y.; Tasaka, M.; Nishimura-Sakurai, Y.; Chen, C.H.; Suda, G.; Mishima, K.; Onuki, Y.; Yamamoto, M.; Maekawa, S.; Enomoto, N.; Kanai, T.; Tsuchiya, K.; Watanabe, M. Two flavonoids extracts from Glycyrrhizae radix inhibit in vitro hepatitis C virus replication. Hepatol. Res., 2009, 39(1), 60-69. doi: 10.1111/j.1872-034X.2008.00398.x PMID: 18647187
  52. Li, J.J.; Liu, M.L.; Lv, J.N.; Chen, R.L.; Ding, K.; He, J.Q. Polysaccharides from platycodonis radix ameliorated respiratory syncytial virus-induced epithelial cell apoptosis and inflammation through activation of mir-181a-mediated hippo and SIRT1 pathways. Int. Immunopharmacol., 2022, 104, 108510. doi: 10.1016/j.intimp.2021.108510 PMID: 34999393
  53. Lee, H.; Spandidos, D.; Tsatsakis, A.; Margina, D.; Izotov, B.; Yang, S. Neuroprotective effects of Scrophularia buergeriana extract against glutamate-induced toxicity in SH-SY5Y cells. Int. J. Mol. Med., 2019, 43(5), 2144-2152. doi: 10.3892/ijmm.2019.4139 PMID: 30896788
  54. Wu, Q.; Coumoul, X.; Grandjean, P.; Barouki, R.; Audouze, K. Endocrine disrupting chemicals and COVID-19 relationships: A computational systems biology approach. Environ. Int., 2021, 157, 106232. doi: 10.1016/j.envint.2020.106232 PMID: 33223326
  55. Pacha, O.; Sallman, M.A.; Evans, S.E. COVID-19: A case for inhibiting IL-17? Nat. Rev. Immunol., 2020, 20(6), 345-346. doi: 10.1038/s41577-020-0328-z PMID: 32358580
  56. Barron, E.; Bakhai, C.; Kar, P.; Weaver, A.; Bradley, D.; Ismail, H.; Knighton, P.; Holman, N.; Khunti, K.; Sattar, N.; Wareham, N.J.; Young, B.; Valabhji, J. Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: A whole-population study. Lancet Diabetes Endocrinol., 2020, 8(10), 813-822. doi: 10.1016/S2213-8587(20)30272-2 PMID: 32798472
  57. Lian, Y.; Zhu, M.; Chen, J.; Yang, B.; Lv, Q.; Wang, L.; Guo, S.; Tan, X.; Li, C.; Bu, W.; Ding, W.; Jia, X.; Feng, L. Characterization of a novel polysaccharide from Moutan Cortex and its ameliorative effect on AGEs-induced diabetic nephropathy. Int. J. Biol. Macromol., 2021, 176, 589-600. doi: 10.1016/j.ijbiomac.2021.02.062 PMID: 33581205
  58. Schwartz, D.M.; Kanno, Y.; Villarino, A.; Ward, M.; Gadina, M.; O’Shea, J.J. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat. Rev. Drug Discov., 2017, 16(12), 843-862. doi: 10.1038/nrd.2017.201 PMID: 29104284
  59. Cao, Y.; Wei, J.; Zou, L.; Jiang, T.; Wang, G.; Chen, L.; Huang, L.; Meng, F.; Huang, L.; Wang, N.; Zhou, X.; Luo, H.; Mao, Z.; Chen, X.; Xie, J.; Liu, J.; Cheng, H.; Zhao, J.; Huang, G.; Wang, W.; Zhou, J. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial. J. Allergy Clin. Immunol., 2020, 146(1), 137-146.e3. doi: 10.1016/j.jaci.2020.05.019 PMID: 32470486
  60. Spinelli, F.R.; Conti, F.; Gadina, M. HiJAKing SARS-CoV-2? The potential role of JAK inhibitors in the management of COVID-19. Sci. Immunol., 2020, 5(47), eabc5367. doi: 10.1126/sciimmunol.abc5367 PMID: 32385052
  61. Jacobs, J.; Clark-Snustad, K.; Lee, S. Case report of a SARS-CoV-2 infection in a patient with ulcerative colitis on tofacitinib. Inflamm. Bowel Dis., 2020, 26(7), e64. doi: 10.1093/ibd/izaa093 PMID: 32342098
  62. Luo, W.; Li, Y.X.; Jiang, L.J.; Chen, Q.; Wang, T.; Ye, D.W. Targeting JAK-STAT signaling to control cytokine release syndrome in COVID-19. Trends Pharmacol. Sci., 2020, 41(8), 531-543. doi: 10.1016/j.tips.2020.06.007 PMID: 32580895
  63. Guoquan, W.; Sha, L.; Xu, C.; Jie, L.; Peng, Z.; Linzhong, Y.; Enhu, Z.; Jiayi, D. Intervention of qingwen baidu decoction on p38MAPK and JAK2/STAT3 signaling pathway in rats with sepsis-induced acute lung injury. Chin. Med. J., 2018, 33(11), 2076-2082.
  64. Tay, M.Z.; Poh, C.M.; Rénia, L.; MacAry, P.A.; Ng, L.F.P. The trinity of COVID-19: Immunity, inflammation and intervention. Nat. Rev. Immunol., 2020, 20(6), 363-374. doi: 10.1038/s41577-020-0311-8 PMID: 32346093
  65. Iwai, K. Diverse ubiquitin signaling in NF-κB activation. Trends Cell Biol., 2012, 22(7), 355-364. doi: 10.1016/j.tcb.2012.04.001 PMID: 22543051
  66. Lee, J.S.; Park, S.; Jeong, H.W.; Ahn, J.Y.; Choi, S.J.; Lee, H.; Choi, B.; Nam, S.K.; Sa, M.; Kwon, J.S.; Jeong, S.J.; Lee, H.K.; Park, S.H.; Park, S.H.; Choi, J.Y.; Kim, S.H.; Jung, I.; Shin, E.C. Immunophenotyping of COVID-19 and influenza highlights the role of type I interferons in development of severe COVID-19. Sci. Immunol., 2020, 5(49), eabd1554. doi: 10.1126/sciimmunol.abd1554 PMID: 32651212
  67. Wu, Y.; Ma, L.; Cai, S.; Zhuang, Z.; Zhao, Z.; Jin, S.; Xie, W.; Zhou, L.; Zhang, L.; Zhao, J.; Cui, J. RNA-induced liquid phase separation of SARS-CoV-2 nucleocapsid protein facilitates NF-κB hyper-activation and inflammation. Signal Transduct. Target. Ther., 2021, 6(1), 167. doi: 10.1038/s41392-021-00575-7 PMID: 33895773
  68. Fei, W.; Xianfang, L.; Zhao, W.; Xiaojuan, L.; Changzhi, Z. Experimental study of qingwen baidu decoction on the expression of NF-κBp65 in lung tissue of rats with acute lung injury. J. Tradit. Chin. Med., 2011, 29(06), 1290-1295.
  69. Ma-Lauer, Y.; Carbajo-Lozoya, J.; Hein, M.Y.; Müller, M.A.; Deng, W.; Lei, J.; Meyer, B.; Kusov, Y.; von Brunn, B.; Bairad, D.R.; Hünten, S.; Drosten, C.; Hermeking, H.; Leonhardt, H.; Mann, M.; Hilgenfeld, R.; von Brunn, A. p53 down-regulates SARS coronavirus replication and is targeted by the SARS-unique domain and PL provia E3 ubiquitin ligase RCHY1. Proc. Natl. Acad. Sci., 2016, 113(35), E5192-E5201. doi: 10.1073/pnas.1603435113 PMID: 27519799
  70. Liu, G.; Park, Y.J.; Tsuruta, Y.; Lorne, E.; Abraham, E. p53 Attenuates lipopolysaccharide-induced NF-kappaB activation and acute lung injury. J. Immunol., 2009, 182(8), 5063-5071. doi: 10.4049/jimmunol.0803526 PMID: 19342686
  71. Uddin, M.A.; Akhter, M.S.; Kubra, K.T.; Barabutis, N. P53 deficiency potentiates LPS-Induced acute lung injury in vivo. Curr. Res. Physiol., 2020, 3, 30-33. doi: 10.1016/j.crphys.2020.07.001 PMID: 32724900
  72. Singh, N.; Bharara Singh, A. S2 subunit of SARS-nCoV-2 interacts with tumor suppressor protein p53 and BRCA: An in silico study. Transl. Oncol., 2020, 13(10), 100814. doi: 10.1016/j.tranon.2020.100814 PMID: 32619819
  73. Allen, S.P.; Seehra, R.S.; Heath, P.R.; Hall, B.P.C.; Bates, J.; Garwood, C.J.; Matuszyk, M.M.; Wharton, S.B.; Simpson, J.E. Transcriptomic analysis of human astrocytes in vitro reveals hypoxia-induced mitochondrial dysfunction, modulation of metabolism, and dysregulation of the immune response. Int. J. Mol. Sci., 2020, 21(21), 8028. doi: 10.3390/ijms21218028 PMID: 33126586
  74. Codo, A.C.; Davanzo, G.G.; Monteiro, L.B.; de Souza, G.F.; Muraro, S.P.; Virgilio-da-Silva, J.V.; Prodonoff, J.S.; Carregari, V.C.; de Biagi Junior, C.A.O.; Crunfli, F.; Jimenez Restrepo, J.L.; Vendramini, P.H.; Reis-de-Oliveira, G.; Bispo dos Santos, K.; Toledo-Teixeira, D.A.; Parise, P.L.; Martini, M.C.; Marques, R.E.; Carmo, H.R.; Borin, A.; Coimbra, L.D.; Boldrini, V.O.; Brunetti, N.S.; Vieira, A.S.; Mansour, E.; Ulaf, R.G.; Bernardes, A.F.; Nunes, T.A.; Ribeiro, L.C.; Palma, A.C.; Agrela, M.V.; Moretti, M.L.; Sposito, A.C.; Pereira, F.B.; Velloso, L.A.; Vinolo, M.A.R.; Damasio, A.; Proença-Módena, J.L.; Carvalho, R.F.; Mori, M.A.; Martins-de-Souza, D.; Nakaya, H.I.; Farias, A.S.; Moraes-Vieira, P.M. Elevated glucose levels favor SARS-CoV-2 infection and monocyte response through a HIf-1α/glycolysis-dependent axis. Cell Metab., 2020, 32(3), 437-446.e5. doi: 10.1016/j.cmet.2020.07.007
  75. Sahu, K.; Kumar, R. Role of 2-Deoxy-D-Glucose (2-DG) in COVID-19 disease: A potential game-changer. J. Family Med. Prim. Care, 2021, 10(10), 3548-3552. doi: 10.4103/jfmpc.jfmpc_1338_21 PMID: 34934645
  76. Singh, R.; Gupta, V.; Kumar, A.; Singh, K. 2-Deoxy-D-Glucose: A novel pharmacological agent for killing hypoxic tumor cells, oxygen dependence-lowering in COVID-19, and other pharmacological activities. Adv. Pharmacol. Pharm. Sci., 2023, 2023, 1-15. doi: 10.1155/2023/9993386 PMID: 36911357
  77. Jahani, M.; Dokaneheifard, S.; Mansouri, K. Hypoxia: A key feature of COVID-19 launching activation of HIF-1 and cytokine storm. J. Inflamm., 2020, 17(1), 33. doi: 10.1186/s12950-020-00263-3 PMID: 33139969
  78. Tannahill, G.M.; Curtis, A.M.; Adamik, J.; Palsson-McDermott, E.M.; McGettrick, A.F.; Goel, G.; Frezza, C.; Bernard, N.J.; Kelly, B.; Foley, N.H.; Zheng, L.; Gardet, A.; Tong, Z.; Jany, S.S.; Corr, S.C.; Haneklaus, M.; Caffrey, B.E.; Pierce, K.; Walmsley, S.; Beasley, F.C.; Cummins, E.; Nizet, V.; Whyte, M.; Taylor, C.T.; Lin, H.; Masters, S.L.; Gottlieb, E.; Kelly, V.P.; Clish, C.; Auron, P.E.; Xavier, R.J.; O’Neill, L.A.J. Succinate is an inflammatory signal that induces IL-1β through HIF-1α. Nature, 2013, 496(7444), 238-242. doi: 10.1038/nature11986 PMID: 23535595
  79. Villarino, A.V.; Kanno, Y.; Ferdinand, J.R.; O’Shea, J.J. Mechanisms of Jak/STAT signaling in immunity and disease. J. Immunol., 2015, 194(1), 21-27. doi: 10.4049/jimmunol.1401867 PMID: 25527793
  80. Zhao, J.; Yu, H.; Liu, Y.; Gibson, S.A.; Yan, Z.; Xu, X.; Gaggar, A.; Li, P.K.; Li, C.; Wei, S.; Benveniste, E.N.; Qin, H. Protective effect of suppressing STAT3 activity in LPS-induced acute lung injury. Am. J. Physiol. Lung Cell. Mol. Physiol., 2016, 311(5), L868-L880. doi: 10.1152/ajplung.00281.2016 PMID: 27638904
  81. Matsuyama, T.; Kubli, S.P.; Yoshinaga, S.K.; Pfeffer, K.; Mak, T.W. An aberrant STAT pathway is central to COVID-19. Cell Death Differ., 2020, 27(12), 3209-3225. doi: 10.1038/s41418-020-00633-7 PMID: 33037393
  82. Zhang, Y.; Xu, M.; Zhang, X.; Chu, F.; Zhou, T. MAPK/c-Jun signaling pathway contributes to the upregulation of the anti-apoptotic proteins Bcl-2 and Bcl-xL induced by Epstein-Barr virus-encoded BARF1 in gastric carcinoma cells. Oncol. Lett., 2018, 15(5), 7537-7544. doi: 10.3892/ol.2018.8293 PMID: 29725459
  83. Deng, Y.; Wang, J.; Huang, M.; Xu, G.; Wei, W.; Qin, H. Inhibition of miR-148a-3p resists hepatocellular carcinoma progress of hepatitis C virus infection through suppressing c-Jun and MAPK pathway. J. Cell. Mol. Med., 2019, 23(2), 1415-1426. doi: 10.1111/jcmm.14045 PMID: 30565389
  84. Liu, F.; Shang, Y.X. Sirtuin 6 attenuates epithelial–mesenchymal transition by suppressing the TGF-β1/Smad3 pathway and c-Jun in asthma models. Int. Immunopharmacol., 2020, 82, 106333. doi: 10.1016/j.intimp.2020.106333 PMID: 32143002
  85. Rizk, J.G.; Kalantar-Zadeh, K.; Mehra, M.R.; Lavie, C.J.; Rizk, Y.; Forthal, D.N. Pharmaco-immunomodulatory therapy in COVID-19. Drugs, 2020, 80(13), 1267-1292. doi: 10.1007/s40265-020-01367-z PMID: 32696108
  86. Haga, S.; Yamamoto, N.; Nakai-Murakami, C.; Osawa, Y.; Tokunaga, K.; Sata, T.; Yamamoto, N.; Sasazuki, T.; Ishizaka, Y. Modulation of TNF-α-converting enzyme by the spike protein of SARS-CoV and ACE2 induces TNF-α production and facilitates viral entry. Proc. Natl. Acad. Sci., 2008, 105(22), 7809-7814. doi: 10.1073/pnas.0711241105 PMID: 18490652
  87. Wang, L.; He, W.; Yu, X.; Hu, D.; Bao, M.; Liu, H.; Zhou, J.; Jiang, H. Coronavirus disease 2019 in elderly patients: Characteristics and prognostic factors based on 4-week follow-up. J. Infect., 2020, 80(6), 639-645. doi: 10.1016/j.jinf.2020.03.019 PMID: 32240670
  88. Karki, R.; Sharma, B.R.; Tuladhar, S.; Williams, E.P.; Zalduondo, L.; Samir, P.; Zheng, M.; Sundaram, B.; Banoth, B.; Malireddi, R.K.S.; Schreiner, P.; Neale, G.; Vogel, P.; Webby, R.; Jonsson, C.B.; Kanneganti, T.D. Synergism of TNF-α and IFN-γ triggers inflammatory cell death, tissue damage, and mortality in SARS-CoV-2 infection and cytokine shock syndromes. Cell, 2021, 184(1), 149-168.e17. doi: 10.1016/j.cell.2020.11.025 PMID: 33278357
  89. Hashimoto, N.; Kawabe, T.; Imaizumi, K.; Hara, T.; Okamoto, M.; Kojima, K.; Shimokata, K.; Hasegawa, Y. CD40 plays a crucial role in lipopolysaccharide-induced acute lung injury. Am. J. Respir. Cell Mol. Biol., 2004, 30(6), 808-815. doi: 10.1165/rcmb.2003-0197OC PMID: 14693668
  90. Li, J.; Lu, K.; Sun, F.; Tan, S.; Zhang, X.; Sheng, W.; Hao, W.; Liu, M.; Lv, W.; Han, W. Panaxydol attenuates ferroptosis against LPS-induced acute lung injury in mice by Keap1-Nrf2/HO-1 pathway. J. Transl. Med., 2021, 19(1), 96. doi: 10.1186/s12967-021-02745-1 PMID: 33653364
  91. Eijk, L.E.; Binkhorst, M.; Bourgonje, A.R.; Offringa, A.K.; Mulder, D.J.; Bos, E.M.; Kolundzic, N.; Abdulle, A.E.; Voort, P.H.J.; Olde Rikkert, M.G.M.; Hoeven, J.G.; Dunnen, W.F.A.; Hillebrands, J.L.; Goor, H. COVID‐19: Immunopathology, pathophysiological mechanisms, and treatment options. J. Pathol., 2021, 254(4), 307-331. doi: 10.1002/path.5642 PMID: 33586189

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2024 Bentham Science Publishers